Core Viewpoint - InMed Pharmaceuticals' INM-901 shows statistically significant reduction in neuroinflammation in a long-term preclinical study for Alzheimer's Disease, indicating its potential as a promising drug candidate [1][2][6]. Group 1: Study Results - INM-901 demonstrated a reduction in several neuroinflammation markers in an amyloid-induced Alzheimer's disease model, suggesting its ability to lower neuroinflammation [2][3]. - The study showed a statistically significant reduction in pro-inflammatory cytokines such as TNF-α, IL-1ß, and INF-γ, which are associated with Alzheimer's disease [4][7]. - A significant reduction in the neurodegeneration biomarker neurofilament light chain (NfL) was observed in the high dose treated group, indicating decreased cellular damage [4][3]. Group 2: Mechanisms of Action - INM-901 is believed to have multiple mechanisms of action, including engagement with CB1/CB2 receptors and PPAR, which are important in neuroprotection and inflammation modulation [6][11]. - The drug's ability to reduce key neuroinflammatory genes such as GFAP, CD-33, and TLR-2 was supported by mRNA assessments, further validating the study's findings [4][3]. Group 3: Future Directions - The company is conducting further molecular analyses to better define the mechanisms of action and potential role of INM-901 in Alzheimer's treatment [2][5]. - Additional evaluations will focus on neuritogenesis and neuroprotection, assessing markers for neuronal differentiation and cellular growth/survival [10][11].
InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study